SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS posts strong growth but remains unprofitable despite a major cash raise.

What the company is saying

SOPHiA GENETICS frames its Q2 2026 update around robust revenue growth, improved operational metrics, and a strengthened balance sheet. The company highlights a 27% year-over-year revenue increase to $23.3 million and a 27% improvement in adjusted EBITDA loss, while net loss remains flat at $22.4 million. Management raises full-year 2026 revenue guidance to $94–96 million, emphasizing confidence in continued expansion. The announcement spotlights operational milestones such as record analyses performed, a growing customer base, and high Net Dollar Retention. Strategic partnerships, including a multi-year agreement with AstraZeneca and an MOU with Memorial Sloan Kettering, are mentioned to suggest future upside, though no financial details are provided. The tone is upbeat and forward-looking, with CEO Ross Muken positioned as the face of the company’s ambitions. The narrative stresses momentum and future profitability, but omits discussion of ongoing net losses and the absence of near-term profitability.

What the data suggests

The reported $23.3 million in Q2 revenue marks a 27% year-over-year increase, confirming strong top-line momentum. Gross margin declined to 64.6% reported (from 67.0%) and 72.1% adjusted (from 74.4%), indicating some pressure on profitability despite higher sales. Net loss held steady at $22.4 million, showing that revenue gains have not translated into bottom-line improvement. Adjusted EBITDA loss improved by 27% to $8.8 million, signaling better cost control, but the company remains far from profitability. Cash and cash equivalents rose to $107.7 million after an oversubscribed $57.5 million public offering, providing liquidity but reflecting ongoing capital needs. Operational metrics—115,000 analyses performed (+22%), 542 core genomics customers (+52 year-over-year), and 117% Net Dollar Retention—demonstrate expanding market reach and customer stickiness. U.S. revenue and volume growth (64% and 60%, respectively) and 80% growth in Liquid Biopsy revenue are positive, but the lack of detailed financials for new partnerships and the absence of product-level or international breakdowns limit transparency. Most claims are substantiated by data, but partnership announcements lack quantifiable impact.

Analysis

The announcement presents a positive tone, highlighting strong revenue growth, improved adjusted EBITDA loss, and operational milestones. The majority of key claims are realised and supported by numerical evidence, such as revenue, gross margin, and customer growth. However, the company remains unprofitable, with a net loss of $22.4 million flat year-over-year, and only adjusted EBITDA loss showing improvement. Forward-looking statements, such as guidance for 2026 revenue and expectations of breakeven in late 2026/2027, are present but limited in number. The $57.5 million capital raise is significant, but immediate profitability is not achieved, and the benefits of this capital are projected rather than realised. Some partnership announcements (e.g., AstraZeneca, MSK) lack quantifiable impact, contributing to moderate hype. The gap between narrative and evidence is most apparent in the framing of future profitability and partnership potential, while the core financial disclosures are proportionate and transparent.

Risk flags

• ●SOPHiA GENETICS remains unprofitable, with a Q2 net loss of $22.4 million flat year-over-year, and only adjusted EBITDA loss showing improvement. Sustained losses require ongoing access to capital and could pressure future funding rounds if growth stalls.
• ●Gross margin declined both on a reported and adjusted basis (to 64.6% and 72.1%, respectively), which could signal rising costs or pricing pressure. Margin compression may limit the company’s ability to achieve profitability even as revenue grows.
• ●The $57.5 million capital raise in Q2 was necessary to support operations, bringing cash to $107.7 million. This signals high capital intensity and a reliance on external funding to bridge to breakeven, exposing investors to dilution risk if losses persist.
• ●Partnership announcements with AstraZeneca and Memorial Sloan Kettering lack disclosed financial terms, timelines, or quantifiable impact. Without concrete details, these deals may not deliver the implied revenue or strategic benefits, and their actual contribution remains speculative.
• ●Forward-looking guidance for breakeven and profitability is based on management projections, not contractual revenue or cost reductions. If operational momentum slows or costs rise, targets for adjusted EBITDA breakeven in 2026 and profitability in 2027 may not be met.

Bottom line

SOPHiA GENETICS delivers strong revenue and customer growth, with operational improvements reflected in adjusted EBITDA loss, but remains structurally unprofitable and reliant on new capital. The company’s raised guidance and robust U.S. and Liquid Biopsy growth are credible, supported by disclosed numbers. Partnership headlines with AstraZeneca and Memorial Sloan Kettering are not backed by financial specifics, so their impact is unproven. The cash position is healthy for now, but persistent net losses and declining margins highlight ongoing execution and funding risks. For investors, the core business is scaling, but a clear path to sustainable profitability is not yet demonstrated. The most important takeaway: growth is real, but profitability and partnership upside are still promises, not facts.

Announcement summary

(NASDAQ:SOPH) SOPHiA GENETICS reported revenue of $23.3 million for the second quarter ended June 30, 2026, representing a 27% year-over-year increase. Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis, compared to 67.0% reported and 74.4% adjusted in the prior year period. Net loss was $22.4 million, flat year-over-year, while adjusted EBITDA loss improved by 27% to $8.8 million. The company raised its 2026 revenue guidance to a range of $94 million to $96 million, representing 22% to 24% year-over-year growth, up from the prior range of $92 million to $94 million. SOPHiA GENETICS completed an oversubscribed $57.5 million public offering in Q2, bringing cash and cash equivalents to $107.7 million at the end of Q2 2026. The company performed a record 115,000 analyses on SOPHiA DDM™, representing 22% year-over-year volume growth, and reached 542 core genomics customers as of June 30, 2026, up from 490 a year ago. Management expects to approach adjusted EBITDA breakeven by the end of 2026 and cross over to positive adjusted EBITDA in the second half of 2027.

Disagree with this article?